NASDAQ:TPST Tempest Therapeutics (TPST) Stock Price, News & Analysis $7.49 +0.26 (+3.60%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$7.36 -0.13 (-1.74%) As of 08/1/2025 07:25 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Tempest Therapeutics Stock (NASDAQ:TPST) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Tempest Therapeutics alerts:Sign Up Key Stats Today's Range$7.05▼$7.4950-Day Range$5.98▼$8.9552-Week Range$5.33▼$28.34Volume28,980 shsAverage Volume91,414 shsMarket Capitalization$27.56 millionP/E RatioN/ADividend YieldN/APrice Target$30.00Consensus RatingModerate Buy Company Overview Tempest Therapeutics, Inc., a clinical-stage oncology company, develops small molecule therapeutics that combine both tumor-targeted and immune-mediated mechanisms to treat various tumors. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, which is in a Phase 1 trial to treat cancer; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial for the treatment of solid tumors. It also develops TREX-1, an enzyme that regulates cGAS/STING pathway signaling and immune recognition. Tempest Therapeutics, Inc. was incorporated in 2011 and is headquartered in Brisbane, California. Tempest Therapeutics, Inc. operates as a subsidiary of Inception Sciences, Inc. Read More Tempest Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks37th Percentile Overall ScoreTPST MarketRank™: Tempest Therapeutics scored higher than 37% of companies evaluated by MarketBeat, and ranked 695th out of 919 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.3 / 5Analyst RatingModerate Buy Consensus RatingTempest Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 2 buy ratings, 2 hold ratings, and no sell ratings.Amount of Analyst CoverageTempest Therapeutics has received no research coverage in the past 90 days.Read more about Tempest Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Tempest Therapeutics are expected to grow in the coming year, from ($1.39) to ($1.05) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Tempest Therapeutics is -0.42, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Tempest Therapeutics is -0.42, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioTempest Therapeutics has a P/B Ratio of 1.32. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Tempest Therapeutics' valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted4.93% of the float of Tempest Therapeutics has been sold short.Short Interest Ratio / Days to CoverTempest Therapeutics has a short interest ratio ("days to cover") of 1.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Tempest Therapeutics has recently decreased by 49.08%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldTempest Therapeutics does not currently pay a dividend.Dividend GrowthTempest Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted4.93% of the float of Tempest Therapeutics has been sold short.Short Interest Ratio / Days to CoverTempest Therapeutics has a short interest ratio ("days to cover") of 1.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Tempest Therapeutics has recently decreased by 49.08%, indicating that investor sentiment is improving significantly. News and Social Media0.0 / 5News SentimentN/A News Coverage This WeekMarketBeat has tracked 1 news article for Tempest Therapeutics this week, compared to 1 article on an average week.Search InterestOnly 3 people have searched for TPST on MarketBeat in the last 30 days. This is a decrease of -25% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Tempest Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Tempest Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.70% of the stock of Tempest Therapeutics is held by insiders.Percentage Held by InstitutionsOnly 22.52% of the stock of Tempest Therapeutics is held by institutions.Read more about Tempest Therapeutics' insider trading history. Receive TPST Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Tempest Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address TPST Stock News HeadlinesTempest Therapeutics (NASDAQ:TPST) Trading Up 4.1% - What's Next?July 29, 2025 | americanbankingnews.comTempest Therapeutics’ Promising Advances in Liver Cancer TreatmentJuly 3, 2025 | tipranks.comTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger the biggest forced rotation of capital since World War II. They reveal why Trump is mobilizing America’s tech giants… and name the two stocks most likely to soar as trillions shift behind the scenes. | Porter & Company (Ad)Tempest Therapeutics Receives NMPA Approval for Pivotal Trial of Amezalpat in Hepatocellular Carcinoma Treatment in China - NasdaqJuly 2, 2025 | nasdaq.comTempest Receives Clearance to Proceed with Pivotal Trial of Amezalpat Combination Therapy for First-Line HCC in ChinaJune 30, 2025 | globenewswire.comTPST - Tempest Therapeutics Inc Valuation - MorningstarJune 27, 2025 | morningstar.comMTPST Tempest Therapeutics, Inc. - Seeking AlphaJune 27, 2025 | seekingalpha.comTempest announces $4.6 million registered direct offering of common stock; shares decline over 13%June 11, 2025 | msn.comSee More Headlines TPST Stock Analysis - Frequently Asked Questions How have TPST shares performed this year? Tempest Therapeutics' stock was trading at $10.8485 at the beginning of 2025. Since then, TPST shares have decreased by 31.0% and is now trading at $7.49. How were Tempest Therapeutics' earnings last quarter? Tempest Therapeutics, Inc. (NASDAQ:TPST) issued its quarterly earnings results on Tuesday, May, 13th. The company reported ($3.16) earnings per share (EPS) for the quarter, beating the consensus estimate of ($3.71) by $0.55. When did Tempest Therapeutics' stock split? Tempest Therapeutics's stock reverse split before market open on Friday, June 25th 2021.The 1-15 reverse split was announced on Friday, June 25th 2021. The number of shares owned by shareholders was adjusted after the closing bell on Monday, June 28th 2021. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split. Who are Tempest Therapeutics' major shareholders? Top institutional shareholders of Tempest Therapeutics include Belvedere Trading LLC. Insiders that own company stock include Versant Venture Capital Vi, L, Stephen R Brady, Justin Trojanowski and Samuel Whiting. View institutional ownership trends. How do I buy shares of Tempest Therapeutics? Shares of TPST stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Tempest Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Tempest Therapeutics investors own include Meta Platforms (META), Cloudflare (NET), NVIDIA (NVDA), Snowflake (SNOW), Tesla (TSLA), Intel (INTC) and Pfizer (PFE). Company Calendar Last Earnings5/13/2025Today8/02/2025Next Earnings (Estimated)8/14/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - DRUGS Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:TPST CIK1544227 Webwww.millendo.com Phone415-798-8589FaxN/AEmployees20Year Founded2012Price Target and Rating Average Price Target for Tempest Therapeutics$30.00 High Price Target$65.00 Low Price Target$9.00 Potential Upside/Downside+300.5%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage4 Analysts Profitability EPS (Trailing Twelve Months)($17.98) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$41.84 million Net MarginsN/A Pretax MarginN/A Return on Equity-305.51% Return on Assets-119.74% Debt Debt-to-Equity RatioN/A Current Ratio1.70 Quick Ratio1.70 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$5.66 per share Price / Book1.32Miscellaneous Outstanding Shares3,680,000Free Float3,509,000Market Cap$27.56 million OptionableOptionable Beta-1.93 Social Links The 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report This page (NASDAQ:TPST) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredBuffett to put 90% of his money in this one stock?CPA and CFA says you have WAY too many stocks - just buy these 3 After years working at the biggest accoun...Altimetry | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredDigital Dollar Alert: Protect Your Wealth Before It’s Too Late134 countries are developing Central Bank Digital Currencies — and the U.S. is quietly testing one. Experts...American Alternative | SponsoredChina just unlocked Nvidia’s AI chips—what that means for youTired of Missing Big AI Moves Like Nvidia? You’re not the problem—your trading system is. Tim’s XGPT system...Timothy Sykes | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredWhy AMZN, GOOG, MSFT might destroy NVDAInvesting Legend Hints the End May be Near for These 3 Iconic Stocks Futurist Eric Fry say Amazon, Tesla an...InvestorPlace | SponsoredYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tempest Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Tempest Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.